Nourianz is supplied in 20 and 40mg tablet strengths. Dosage adjustments are recommended in patients with hepatic impairment, those taking strong CYP43A4 inhibitors, as well as tobacco smokers.

KW-6356 is a follow-up to Kyowa Kirin's first-generation adenosine A2 antagonist Nourianz/Nouriast (istradefylline), which finally claimed FDA approval in 2019 as an add-on to levodopa in ...

Nourianz (istradefylline) is sometimes prescribed alongside carbidopa and levodopa. Although its exact mechanism of action is unknown, it is believed to block adenosine receptors. It is ...

2, 3, 4 NOURIANZ ® (istradefylline) is prescription medication indicated as adjunctive treatment to levodopa/carbidopa in adult patients with PD experiencing "off" episodes. Patients with ...

The effort includes an updated patient website (www.Nourianz.com) with dynamic content, a patient video, and resources that explain the role of dopamine and adenosine in Parkinson's disease ...